These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19505958)

  • 1. Functional interaction of mammalian target of rapamycin complexes in regulating mammalian cell size and cell cycle.
    Rosner M; Fuchs C; Siegel N; Valli A; Hengstschläger M
    Hum Mol Genet; 2009 Sep; 18(17):3298-310. PubMed ID: 19505958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1.
    Rosner M; Hengstschläger M
    Hum Mol Genet; 2008 Oct; 17(19):2934-48. PubMed ID: 18614546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.
    Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH
    J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
    García-Martínez JM; Alessi DR
    Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Protor as a novel Rictor-binding component of mTOR complex-2.
    Pearce LR; Huang X; Boudeau J; Pawłowski R; Wullschleger S; Deak M; Ibrahim AF; Gourlay R; Magnuson MA; Alessi DR
    Biochem J; 2007 Aug; 405(3):513-22. PubMed ID: 17461779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1.
    Guertin DA; Stevens DM; Thoreen CC; Burds AA; Kalaany NY; Moffat J; Brown M; Fitzgerald KJ; Sabatini DM
    Dev Cell; 2006 Dec; 11(6):859-71. PubMed ID: 17141160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of rictor as a novel substrate of Polo-like kinase 1.
    Shao T; Liu X
    Cell Cycle; 2015; 14(5):755-60. PubMed ID: 25714006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2.
    Huang J; Dibble CC; Matsuzaki M; Manning BD
    Mol Cell Biol; 2008 Jun; 28(12):4104-15. PubMed ID: 18411301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
    Zou Z; Chen J; Yang J; Bai X
    Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR has a developmental stage-specific role in mitochondrial fitness independent of conventional mTORC1 and mTORC2 and the kinase activity.
    Kalim KW; Zhang S; Chen X; Li Y; Yang JQ; Zheng Y; Guo F
    PLoS One; 2017; 12(8):e0183266. PubMed ID: 28813526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
    Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
    J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
    Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
    PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin regulates the phosphorylation of rictor.
    Akcakanat A; Singh G; Hung MC; Meric-Bernstam F
    Biochem Biophys Res Commun; 2007 Oct; 362(2):330-3. PubMed ID: 17707343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2.
    Luo Y; Liu L; Wu Y; Singh K; Su B; Zhang N; Liu X; Shen Y; Huang S
    Oncotarget; 2015 Feb; 6(6):4286-98. PubMed ID: 25738366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation.
    Wang L; Harris TE; Lawrence JC
    J Biol Chem; 2008 Jun; 283(23):15619-27. PubMed ID: 18372248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
    Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR.
    Yin Y; Hua H; Li M; Liu S; Kong Q; Shao T; Wang J; Luo Y; Wang Q; Luo T; Jiang Y
    Cell Res; 2016 Jan; 26(1):46-65. PubMed ID: 26584640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
    Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
    Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.
    Julien LA; Carriere A; Moreau J; Roux PP
    Mol Cell Biol; 2010 Feb; 30(4):908-21. PubMed ID: 19995915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.